Due to the relatively low receptor density of MC1R in melanoma, high molar activity and low injected peptide mass (< 50 pmol per animal) is required for radiopharmaceuticals targeting this receptor to have a good tumour uptake without saturating (blocking) the receptors. Here, MC1R is linked to neoplasm.